Stay updated with breaking news from Marek Ciszewski. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA - - Junshi Biosciences and Coherus are actively engaged in ongoing discussions... | December 25, 2022
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) GlobeNewswire December 25, 2022 - FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the...
Toripalimab in combination with chemotherapy was associated with significant improvements in PFS and OS compared with chemotherapy alone in patients with advanced NSCLC without EGFR/ALK mutations, regardless
Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022 - read this article along with other careers information, tips and advice on BioSpace
REDWOOD CITY, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that...